Part 2 - Modelling a Better Dose: Using MIDD to meet Regulatory Expectations & Make Smarter Decisions in Drug Development In the previous blog post, we introduced the FDA guidance “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases”, concepts related to Project Optimus and how these impact different parts of the industry. This time, we want to dig...
Read More